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Cysteine- rich secretory protein 3 (CRISP3) prognostic significance in prostate cancer (PCA) has generated mixed
result. Herein, we investigated and independently validated CRISP3 expression in relation to ERG and PTEN genomic
aberrations and clinical outcome. CRISP3 protein expression was examined by immunohistochemistry using a
cohort of patients with localized PCA (n = 215) and castration resistant PCA (CRPC) (n = 46). The Memorial Sloan
Kettering (MSKCC) and Swedish cohorts were used for prognostic validation. Results showed, CRISP3 protein
intensity to be significantly associated with neoplastic epithelium, being highest in CRPC vs. benign prostate tissue
(p < 0.0001), but was not related to Gleason score (GS). CRISP3 mRNA was significantly associated with higher GS
(p = 0.022 in MSKCC, p = 1.1e-4 in Swedish). Significant association between CRISP3 expression and clinical outcome
was documented at the mRNA but not the protein expression levels. CRISP3 mRNA expression was related to
biochemical recurrence in the MSKCC (p = 0.038) and lethal disease in the Swedish cohort (p = 0.0086) and retained
its prognostic value in the subgroup of patients with GS 6 & 7. Furthermore, CRISP3 protein and mRNA expression
was significantly associated with positive ERG status and with PTEN deletions. Functional biology analysis
documented phenylalanine metabolism as the most significant pathway governing high CRISP3 and ERG expression
in this subtype of PCA. In conclusion, the combined status of CRISP3, ERG and PTEN define a molecular subtype of
PCA with poorest and lethal outcome. Assessing their combined value may be of added value in stratifying patients
into different prognostic groups and identify those with poorest clinical outcome.
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Prostate cancer (PCA) remains a major cancer in the
western countries and ranks as the second leading cause
of cancer related deaths among men [1]. Although PCA
shows different biological behaviour in its disease pro-
gression and clinical course, there is strong correlation
between pathological prognostic parameters and clinical
outcome. In the past decade, several genomic studies
have implemented methods to mark specific genomic al-
terations associated with disease progression and* Correspondence: tarek.bismar@cls.ab.ca
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unless otherwise stated.categorize PCA into molecular subtypes with proposed
prognostic and therapeutic subgroups. However, cur-
rently, those road maps are still being built and refined
to better allow physicians to accurately offer better tar-
geted treatment options for PCA patients.
Cysteine- rich secretory protein 3 (CRISP3) is a mem-
ber of large family of cysteine- rich secretory proteins
that are expressed in vertebrates, insects, plants, fungi,
and yeast [2-6]. In humans, CRISP3 mRNA is expressed
predominantly in salivary gland, prostate, and pancreas,
and at much lower levels in epididymis, thymus, ovary,
testis, colon, and lacrimal glands [7,8].
ERG gene rearrangement is the most abundant genomic
aberrations in prostate cancer that accounts for around
50% of clinically localized disease. Furthermore, several
studies have implicated ERG gene rearrangements withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and PTEN aberration has been suggested to signify a dis-
tinct molecular subtype of PCA. However, its prognostic
implication remains unclear.
Recent studies have associated high CRISP3 with ERG-
gene rearrangements and PTEN deletions and upregula-
tion of transcript levels of CRISP3 has been previously
documented in PCA compared to benign prostate tissue
using in situ hybridization [2]. This upregulation was
also confirmed by few other studies [7,9]. However, data
related to the prognostic significance of CRISP 3 has
been mixed with conflicting results [10-14] The aim of
the current study was to investigate CRISP3 protein ex-
pression in large clinical cohort of localized disease and
to assess its expression in relation to ERG gene re-
arrangement and PTEN deletions and across various
stages of disease progression including castration resist-
ant prostate cancer (CRPC). We also aimed to validate
the prognostic value of CRISP3 in conjunction to the
molecular subtype of PCA with ERG and PTEN genomic
aberrations and to utilize bioinformatics to delineate
possible genetic connections and pathways related to
this molecular subtype of prostate cancer.
Material and methods
Study population and Tissue microarray construction
We utilized two cohorts in this study. The first cohort con-
sisted of 215 patients treated by retro-pubic radical prosta-
tectomy for localized prostate cancer between 1992–2004
with a mean follow-up of 4.8 years (range 0–15.8). Clinical
progression was defined as a post-operative serum PSA ele-
vation of >0.2 ng/ml assessed on two occasions following
decrease to non detectable levels. Three tissue microarray
(TMA) blocks were created from this cohort using a man-
ual tissue arrayer (Beecher Instruments, Silver Spring, MD).
Each block was assembled without prior knowledge of any
clinical or pathological staging information. From each
case, one to nine cores (average 3.3), 0.6 mm in diameter,
were sampled from the paraffin embedded tissue blocks,
containing benign, high grade intraepithelial neoplasia
(HGPIN) and prostate cancer (PCA). We sampled both
Gleason pattern originally present in the radical prostatec-
tomy to reflect the average GS from each case. After con-
struction, 4 μm sections were cut and stained with
hematoxylin and eosin on the initial slides to confirm the
histological diagnosis and grading of Gleason score. The pa-
tients’ demographics of this cohort have been previously
described [15,16]. The second cohort consisted of 46 pa-
tients with castration resistant prostate cancer assembled
onto one TMA block. Tissues from those samples were ob-
tained by transurethral resections of prostate preformed to
relieve clinical obstructive symptoms thus representing lo-
cally advanced disease. The study was approved by the Uni-
versity of Calgary ethics review board who waived informedpatients consent. All Clinical and pathological information
of patients were collected under this approval.
Independent validation of mRNA expression data
Two independent prostate cancer expression data were
used to validate the findings from the protein expression
study. The first data is the Memorial Sloan Kettering Can-
cer Center (MSKCC) data [17]. The MSKCC sample data
were downloaded from Gene Expression Omnibus (GEO)
database series GSE21032. All tissues were collected during
Radical prostatectomy surgery, snap frozen in liquid nitro-
gen, and stored at −80°C. Care was taking to identify re-
gions of tumor free from contaminating stroma. The data
has the gene expression of 29 normal samples, 131 primary
tumor samples after Radical prostatectomy, 19 metastasis
samples and 6 cell lines (DU145, LNCaP, LNCaP104R,
LNCaP104S, PC3 and VCaP). Samples had a follow up time
till biochemical relapse for up to 120 months and are
mainly low risk samples. The second data is the Swedish
cohort that was downloaded from GEO series GSE16560
that has expression of 281 localized cancer samples; mainly
Gleason score 7, and follow up time of overall survival for
up 250 months. In the MSKCC data ERG, PTEN status
was determined from expression data using PAM clustering
implemented in cluster R package. In the Swedish data,
ERG was determined by FISH and PTEN was determined
from expression data.
CRISP3 protein expression by immunohistochemistry
(IHC)
4 μm thick TMA sections from formalin-fixed paraffin tis-
sue were cut and stained with Leica auto-stainer Bond-
Max. The slides were pretreated for deparaffinization
followed by heat induced antigen retrieval by Epitope re-
trieval solution 1 (Leica Microsystems, Buffalo Grove, IL,
USA) for 20 minutes, and then incubated for 15 minutes at
room temperature with CRISP3 rabbit polyclonal antibody
(ProteinTech Group, Inc., Chicago, IL, USA) at 1:100 dilu-
tion. Bond polymer Refine Detection kit (Leica Microsys-
tems, Buffalo Grove, IL, USA) was used for DABi detection
and counter stain. A multi-tissue control TMA slide con-
taining samples of various tissue organs was previously
stained and utilized as positive and negative control to con-
firm antibody specificity.
Pathological analysis
All TMA cores were assigned a diagnosis (i.e. benign,
HGPIN or PCA) and confirmed independently by three
pathologists (SAB, SAH and TAB). Gleason scoring was
assessed according to the 2005 ISUP criteria [18]. For
each patient, the two predominant patterns were sam-
pled and included on the TMAs blocks for analysis.
CRISP3 protein expression was examined by two study
pathologists (SAB, SAH) and the intensity of staining
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following parameters: The staining intensity (0, 1+, 2+,
and 3+) for negative, weak, moderate and high intensity
plus the fraction of positive tumor cells were docu-
mented for each tissue spot. A final score was achieved
from these two parameters as follows: Negative(0): ab-
sence of CRISP3 staining in 100% of cells; weak (1): in-
tensity of 1+ in > 70% of tumor cells or staining intensity
of 2+ in ≤30% of tumor cells; moderate(2): intensity of
1+ in >70% of tumor cells, or staining intensity of 2+ in
>30% but ≤ 70% of tumor cells or staining intensity of 3+
≤30% of tumor cells; strong(3): intensity of 2+ in >70%
of tumor cells or staining intensity of 3+ in >30% of
tumor cells. As CRISP3 was noticed to be wealy
expressed in adjacent stromal cells, when we assessed
CRIPS3 expression in our study, we used the expression
of adjacent stromal cells as a control for measuring the
relative expression of epithelial cells.
ERG expression was previously evaluated on this co-
hort based on positive vs. negative expression as vali-
dated and correlated to ERG gene rearrangements using
the break apart FISH probes (data not shown). PTEN de-
letions were previously evaluated and recorded as not
deleted, hemizygous or homozygous deletions by count-
ing 100 nuclei in each core as previously described using
a four color FISH probe [19].
Statistical analysis
Statistical analysis was done to assess various clinical and
pathological variables, means and ranges for continuous
variables. Chi-square tests were conducted to test for asso-
ciations between CRISP3 protein expression and Gleason
score, surgical margin and pathological stage, ERG expres-
sion and PTEN genomic deletions. Wilcoxon statistical test
was used to assess the significance of the difference of
CRISP3 mRNA expression across Gleason score, ERG and
PTEN status in the MSKCC and Swedish cohorts. CRISP3
protein expression in clinically localized prostate cancer
cases association to disease free survival time was assessed
using Cox Proportional Hazards regression analysis and the
Kaplan-Meier curves along with the log-rank test. In all
statistical tests a p value <0.05 was considered significant.
Results
Expression of CRISP3 protein in benign, HGPIN, localized
and castration resistant prostate cancer
A total of 1194 core samples were available for evaluation
in the localized cohort; [benign (n = 175), HGPIN (n = 77),
PCA (n = 942)]. CRISP3 protein expression (reported as
mean ± SD) showed significant increase in PCA (1.71 ±
0.63), compared to benign prostate tissue (1.04 ± 0.42)
(p < 0.0001). In HGPIN, mean CRISP3 protein expression
was comparable to PCA (1.65 ± 0.56) (p = 0.84) and still sig-
nificantly higher than benign prostate tissue (P < 0.0001). Inthe advanced/castration resistant prostate cancer samples
(n = 92), CRISP3 protein mean expression levels were the
highest with mean intensity of (2.09 ± 0.75) compared to all
other types of neoplastic and benign epithelium
(p < 0.0001) (Figure 1).
CRISP3 protein expression in association to Gleason
score, surgical margin, pathological stage and PSA
biochemical relapse
To investigate the association of CRISP3 protein expres-
sion in relation to Gleason score, we grouped samples
based on Gleason score sum of individual TMA cores.
To enable better correlation of CRISP3 protein expres-
sion with GS, CRISP3 protein expression was assessed
as binary value, grouping moderate/high expression vs.
negative/weak. In this cohort, we did not observe associ-
ation between CRISP3 protein expression and GS. Mod-
erate/high CRISP3 protein expression was noted in 25/
68 (36%) of GS < 7 compared with 52/145 (35.8%) of
GS ≥ 7.
Similarly, we did not observe significant relation to
any other clinical or pathological parameters. However, a
non-significant trend toward inverse relation between
moderate/high CRISP3 protein expression and higher
pathological stage was noted. Herein, 19/68 (27%) mod-
erate/high CRISP3 protein expression were noted in pT3
vs. 54/135 (40%) in pT2 (p = 0.09). CRISP3 protein was
not related to disease free survival as measured by post
serum PSA elevation of ≥ 0.2 ng/ml (Figure 2). Table 1 il-
lustrates patients’ demographics in relation to CRISP3
protein expression.
CRISP3 protein expression in relation to ERG expression
and PTEN genomic deletions
To assess the association between CRISP3 protein and
ERG expression, 812 cores of localized prostate cancer
were assessed for the dual expression of both markers.
There was significant association between higher
CRISP3 protein expression and ERG expression. Moder-
ate/high CRISP3 protein expression was present in 217/
316 (69%) in ERG positive vs. 287/496 (58%) in ERG
negative tumor cores (p = 0.002) (Figure 3A).
Since it was previously documented that ERG genomic
rearrangements are enriched for PTEN deletions [20],
we sought to investigate the association of CRISP3 with
PTEN genomic deletions based on the type of PTEN de-
letion present within the individual core sample. Overall,
there was significant association between CRISP3 pro-
tein expression and PTEN deletions (71% vs. 58%) (p =
0.01). To further investigate the relation of the type of
PTEN genomic deletions and CRISP3 protein expres-
sion, we grouped the samples into PTEN intact, hemizy-
gous PTEN deletions and homozygous PTEN deletions.
In this cohort, higher CRISP3 protein expression was
Figure 1 CRISP3 protein expression across different stages of PCA progression. A. Error bars of mean intensity of CRISP3 protein expression
in benign prostate tissue (BN), high grade intraepithelial neoplasia (HGPIN) and localized prostate cancer (PCA). B. Examples of CRISP3 expression
in Benign, HGPIN, localized prostate cancer (PC) and castration resistant prostate cancer (CRPC).
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PTEN genomic aberrations (not deleted vs. hemizygous
vs. homozygous deletions) (Table 2). Moderate/high
CRISP3 protein expression was present in 279/477
(58%) PTEN intact tumors vs. 92/136 (68%) PTEN hemi-
zgous deletions vs. 40/52 (77%) in PTEN homozygous
deleted PCA (P = 0.01) (Figure 3B).CRISP3 expression in PCA Cell lines
To validate CRISP3 mRNA expression relative to ERG
status, we investigated the mRNA expression of CRISP3
and ERG in multiple cell lines from the MSKCC data
(GSE21032). Both CRISP3 and ERG showed two-fold in-
crease in VCaP cell line which harbors TMPRSS2-ERG
rearrangement (Figure 3C). Using VCaP cell line to val-
idate whether CRISP3 mRNA expression is a direct
target of the ERG transcription factor , Ribeiro et al. de-
tected three putative ETS-binding-sites containing-
regions of the CRISP3 promoter in the ERG-bound
chromatin, supporting direct link between ERG and
CRISP3 [13].CRISP3 expression in independent gene expression data
of the MSKCC and Swedish prostate cancer cohorts
We next characterized the expression of CRISP3 with
prostate cancer subtypes and clinical variables at the
mRNA level. We used two public mRNA gene expres-
sion data MSKCC (GSE21032) and the Swedish cohort
(GSE16560) and used Wilcox test to assess the statistical
significance of the association between CRISP3 and
other clinical variables. Analyzing the mRNA expression
of CRISP3 in normal and PCA showed that CRISP3
mRNA expression is significantly upregulated in PCA
(p = 0.0053) and metastasis (p = 4.4e-5) (Figure 3A).
CRISP3 mRNA expression was also significantly associ-
ated with ERG status as determined by mRNA ERG ex-
pression (p = 2.9e−9) and PTEN deletions as determined
by mRNA PTEN expression (p = 0.053) (Figure 3B,C) in
the MSKCC data, and significantly associated with ERG
gene rearrangements in Swedish cohort determined by
FISH (p = 2.5e-7) (Figure 4A).
Investigating relation to Gleason score and grouping
cases into <7 vs. ≥ 7, high CRISP3 mRNA expression
was associated with high GS in both MSKCC (p = 0.022)
Figure 2 Kaplan Meier curves of CRISP3 protein. A. Disease free survival for CRISP3 protein expression in all cases. B. Disease free survival for
CRISP3 protein expression in ERG negative cases, C. Disease free survival for CRISP3 in ERG positive cases. D. Error bars showing percent cases
with CRISP3 protein expression related to ERG rearrangements in prostate cancer. E. Error bars showing percent of CRISP3 expression in PTEN
intact (PTEN+/+), hemizygous (PTEN+/−) and homozygous (PTEN−/−) PTEN deletions prostate cancer. F. mRNA expression levels of CRISP3 and
ERG in multiple cell lines.
Table 1 Patients demographics of the localized cohort stratified based on CRISP3 expression
Parameter Negative/weak (n = 137) Moderate/high (n = 78) p-value
Age (years) (mean; range) 64.53 (43–81) 63.58 (47–78) 0.280
Pre-PSA level (ng/ml) 0.212
= < 10 43 (68%) 28 (80%)
>10 20 (32%) 7 (20%)
Gleason summary 0.750
<7 43 (32%) 25 (33%)
3 + 4 43 (32%) 24 (31%)
4 + 3 31 (22%) 20 (26%)
>7 19 (14%) 8 (10%)
pT-stage 0.091
pT2 81 (62%) 54 (74%)
pT3 49 (38%) 19 (26%)
Surgical margin 0.285
Negative 69 (53%) 45 (61%)
Positive 61 (47%) 29 (39%)
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Figure 3 Expression of CRISP3 mRNA in MSKCC data. A. Association of CRISP3 to prostate cancer progression, B.CRISP3 association to ERG, C.
CRISP3 association to PTEN. D. Association of CRISP3 to Gleason score. E. Kaplan Meier of CRISP3 mRNA expression to time till biochemical
relapse in MSKCC Cohort.
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CRISP3 mRNA expression, determined by PAM cluster-
ing, also was associated with time to biochemical recur-
rence (BCR) after Radical prostatectomy (p = 0.038, HR:
1.15) (Figure 3E), but not BCR event (data not shown).
However, when investigating association to lethal dis-
ease, high CRISP3 mRNA expression was associated
with time to death (p = 0.0066) (Figure 4C) in all sam-
ples of the Swedish cohort and the subsamples in Glea-
son score 7 (p = 0.029) (Figure 4D). Additional analysis
supported the implications of high CRISP3 mRNATable 2 Association between CRISP3 immunostaining and PT
PTEN deletions
Negative/weak CRISP 3 expression n (%)
PTEN not deleted (n) 304(50%)
PTEN hemizygous deletion ( n) 53(35%)
PTEN homozygous deletion (n) 13(24%)
Total (n) 370(45%)
Cases assessed as individual TMA cores.expression in prostate cancer lethality (p = 0.0086)
(Figure 4E).
The biological pathways of genes deregulated in PCA
subset with ERG positive and high CRISP3 mRNA
expression
To analyze the cross-talk between ERG and CRISP3, we
identified the differentially expressed genes from MSKCC
data between ERG positive vs. ERG negative, high CRISP3
mRNA expression vs. low CRISP3 mRNA expression and
ERG positive/ high CRISP3 mRNA expression vs. othersEN intact, hemizygous PTEN deletions and homozygous






Figure 4 Expression of CRISP3 mRNA in Swedish data. A. Association of CRISP3 to ERG, B. Association of CRISP3 to Gleason score, C. Kaplan
Meier demonstrating association of CRISP3 to time to death in all samples regardless of GS, D. Kaplan Meier association of CRISP3 to time to
death in GS = 7 subgroup. E. Association of CRISP3 mRNA expression to cancer lethality in the Swedish cohort.
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used student t-test, adjusting for multiple corrections using
bonferroni method. Herein, we identified a group of 12
genes that are implicated in both CRISP3 and ERG sub-
groups. These 12 genes are highly correlated and interact-
ing with AKT1, TP53, CTNNB1 and FOS network of genes
extracted from the FI reactome functional protein networks
implemented in Cytoscape (Figure 5B) suggesting a critical
role of CRISP3 in cell proliferation [21].
Expression of ERG and CRISP3 mRNA expression is
significantly correlated. Low CRISP3 mRNA expression
was associated with ERG negative, while high CRISP3
mRNA expression was associated with ERG positive.
However, 50% of ERG positive samples has low CRISP3
mRNA expression, suggesting that CRISP3 expression is
conditionally dependent on the expression of ERG or
CRISP3 overexpression is a consequence event of ERG
rearrangement.
We further investigated the functional biology of the
84 genes that are implicated in the ERG positive –high
CRISP3 PCA subtype. These 84 genes were differentially
expressed in only samples with high CRISP3 mRNAexpression and ERG positive samples, and define a dis-
tinct molecular profile of samples. SPINK1 is found to
be differentially expressed in the ERG-positive-high
CRISP3 PCA subtype. Using Gene set enrichment ana-
lysis [22], the 84 genes were enriched in ribosomal
proteins (p = 4.1e-4) and translational elongation process
(p = 0.018) (Table 3). Using network-based enrichment
analysis tool (http://www.enrichnet.org/) to characterize
the biological pathways governing these genes, phenyl-
alanine metabolism was the most significant pathway
that governs the 84 genes. This depicts the molecular
mechanism underlying the combination of ERG and
CRISP3 regulation.
Potential clinical utility of combining ERG, CRISP3 and
PTEN
To confirm the significant association of CRISP3, ERG and
PTEN, we assessed the prognostic value of combining ERG,
PTEN and CRISP3 expression. The mRNA expression
levels of the three genes were extracted from the Swedish
cohort and hierarchical clustering was used to group all
samples based on the three genes’ expression. Clustering
Figure 5 Cross-talk between CRISP3 and ERG. 12 genes are implicated in both CRISP3 and ERG samples (A). The 12 genes are connected to
p53, CTNNB1, AKT1 and other cell proliferation genes (B). A heatmap showing the prognostic value of combining the status of ERG, PTEN and
CRISP3 in samples with GS6 or 3 + 4 in the Swedish data. Hierarchical clustering showed that the three genes define distinct subgroups of
patients with GS6 or 3 + 4 (C). The cluster that is enriched with high ERG, CRISP3 and low PTEN showed poorest survival.
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CRISP3 and low PTEN have marginally poor outcome
(p = 0.053). We then focused on patients with low risk
tumors; with Gleason score 6 or (3 + 4) to investigate
whether this signature is able to stratify patients within this
prognostic ambiguous group (Figure 5C), patients with the
signature of high ERG, high CRISP3 and low PTEN wereTable 3 Top deregulated genes in high CRISP3
expression, ERG positive samples and the pathways they
are involved in
Pathway Top genes in the 84 set
mTORC mediated signaling EIF4B
Unwinding of DNA GINS2
Steroid hormone biosynthesis HSD17B3
Peptide chain elongation RPL4, RPL5, RPS3, RPL17
Protein translation and ribosomes EIF4B, RPL4, RPL5, RPS3, RPL17
Deadenylation of mRNA EIF4B
Signaling by BMP BMPR1Bsignificantly associated with poorest clinical outcome
(p = 0.0057) (Figure 5D).
Discussion
CRISP3 belongs to a large family of cysteine –rich
secretory proteins which are poorly characterized extra-
cellular proteins [14]. This family is highly expressed in
salivary glands and in the male reproductive tract, most
of which are under strong androgen-dependency [13]. In
humans, CRISP3 was first described in neutrophils, but
later it was shown to be highly expressed in several exo-
crine glands, including salivary glands, pancreas and
prostate [2-6] and within different cells of the immune
system including pre-B cells, neutrophils, and eosino-
phils [23,24].
CRISP3 has been previously reported to be overex-
pressed in prostate cancer [7,9,25]. Using in situ
hybridization, Kosari et al. al reported that CRISP3
mRNA expression is epithelial-specific and is up-
regulated in prostate cancer compared with benign
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CRISP3 production came from the prostatic epithelium,
rather than the surrounding stromal tissue [9]. Others
noted that CRISP3 expression increases more than 50
fold in prostate cancer [7]. In our immunohistochemis-
try study we document that CRISP3 protein levels are
highly expressed in all neoplastic prostate epithelium
compared with benign prostate tissue. We also report
for the first time that CRISP3 protein expression is high-
est in the CRPC category. This suggests a key role of
CRISP3 in AR-independent mediated transcriptional
program.
The association between CRISP3 and clinico-
pathological parameters has been investigated in several
previous publications, but with mixed results. Table 4.
Summarizes the results of CRISP3 protein expression in
correlation with clinico-pathological parameters from
five previous studies in addition to our own [10-14].
Bjartell et al. [26] found increased CRISP3 protein ex-
pression in higher grade PCA (Gleason 4 and 5). How-
ever in a subsequent study by the same author, no
significant difference in GS between patients with posi-
tive and negative CRISP3 was noted [12]. The associ-
ation between GS and CRISP3 protein expression was
only evident in one more study by Grupp et al., but was
not demonstrated in three other. In our study, we were
not able to document any association between CRISP3
and GS at the protein level; however, at the mRNA levels
we document significant positive association with higher
GS. One possible explanation to this discripancy could
be related to the inclusion of adjacent stromal cells in
the mRNA expression assessment (Taylor et al.) where
stromal cells had indeed expressed lower levels of
CRISP3, though the authors dissected the samples care-
fully to ensure minimal contamination of tumor samples
with non-neoplastic tissue. Moreover, the relation of
CRISP3 to other pathological parameters, was only doc-
umented in one study (pathological stage and surgical
margin) with all other 4 studies including ours failing to
show such association. These data suggest either thatTable 4 Results of CRISP3 expression in correlation with clinic
Study Correlation of CRISP 3 expressio
Gleason score Patholo
Ribeiro et al. [13] No N
Grupp et al. [14] Yes
Dahlman et al. [10] No?
Hoogland et al. [11] No
Bjartell et al. [12] No
Al-Bashir et al. No
*There was a trend that patients with high CRISP3 expression had higher risk of bio
¶Adding CRISP3 expression to current parameters does not provide any added sign
†Using non-parametric tests on the qRT-PCR data from the validation series.
μBased on protein expression. However, mRNA CRISP3 levels were prognostic basedmorphological assessment of CRISP3 protein expression
is inaccurate due to potential heterogeneity or protein
abundance or that CRISP3 is not actually related to GS
and other pathological parameters and hence provide
added value beyond those of current pathological pa-
rameters. The latter is more likely given that CRISP 3
mRNA expression was significantly associated to time of
biochemical relapse and lethal disease in the MSKCC
and Swedish cohorts.
CRISP3 has been reported to be one of the top genes
that are linked to TMPRSS2-ERG positive prostate can-
cer with about 53-fold increase when compared with fu-
sion negative prostate cancer [13]. Our study confirms
this strong association.
It is well known that up to 40% of human prostate
cancers show loss of at least one copy of the PTEN gene
via submicroscopic deletion [27-29] and that the percent
of tumors harboring PTEN deletions increases with dis-
ease progression and in advanced castration resistant
disease [19,20]. Moreover, the complexity of PTEN dele-
tions increases with higher Gleason score and is tightly
associated with ERG rearrangement [8,20,28-31]. In this
study, we carried out a detailed investigation between
CRISP3 protein expression and the type of PTEN dele-
tions which was only partially addressed in the study by
Grupp et al. [14], where they documented significant as-
sociation between PTEN deletions and CRIPS3 protein
expression. However, the relation between the type of
PTEN deletion and CRISP3 protein expression was not
addressed. Herein, we confirm significant increase in
CRISP3 protein expression not only in PTEN deleted tu-
mors, but also document that this expression is also
connected and increases with the degree and severity of
PTEN deletion (hemizygous vs. homozygous) (65% vs.
76%) respectively.
We also investigated the potential linkage between
CRISP3 mRNA expression and ERG gene rearrange-
ments and identified a 12-gene signature that is impli-
cated in both CRISP3 and ERG subgroup of PCA. We
also investigated the functional biology of an 84 geneso-pathological parameters from comparatives studies
n with clinico-pathological parameters
gical stage Surgical margins Outcome







ificance to the prediction.
on the validation within Taylor and Swedish cohorts.
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mRNA expression PCA subtype, documenting phenyl-
alanine metabolism as the most significant and likely
pathway that governs these genes. This correlation sug-
gests that CRISP3 is a major target of ERG that is
strongly overexpressed in PCA.
Although our study did not provide any prognostic
implication of CRISP3 expression in prostate cancer at
the protein level, we were able to confirm significant
prognostic value for CRISP3, in the MSKCC and
Swedish cohorts. This may be due to heterogeneity or
the methods used to assess for protein expression and
highlight the need for more accurate measurement of
protein expression, likely through the use of image ana-
lysis systems. The tight link between CRISP3 expression,
ERG gene rearrangements and/ or PTEN deletions in
the three cohorts of prostate cancer studied, suggest the
presence of distinct molecular alterations in this sub-
group of tumors that may have additional clinical impli-
cation if assessed collectively.
In this study, we validated the prognostic value of the
combined status of the three genes by clustering
the samples in the Swedish data into multiple clusters.
The clustering showed that the status of the three genes
can stratify patients into distinct subgroups with distinct
outcome. The cluster that is enriched with high ERG,
high CRISP3 and low PTEN demonstrated the poorest
survival outcome and this was evident in the group of
patients with GS6 & (3 + 4), which is the most group
likely to benefit of signature biomarker. This finding is
novel and has not been shown in any previous study, in-
cluding the study by Grupp et al. in which association of
CRISP3 was noted with ERG and PTEN, but it failed to
document any added prognostic value for the three
markers combined [14].
In Summary, in this study we confirmed significant as-
sociation between CRISP3 expression and prostate can-
cer progression as well as a strong link between CRISP3
expression and each of ERG expression and PTEN gen-
omic deletions. In addition, we documented and detailed
potential genes that are tightly connecting this molecular
subtype of PCA. More importantly, we confirm and for
the first time, that tumors defined by CRISP3, ERG and
PTEN signify a molecular subtype of PCA with the
poorest clinical outcome. This suggests that the combin-
ation of the three genes could be used as a molecular
test to stratify patients’ risk. Further studies to elucidate
the molecular network connecting CRISP3, ERG and
PTEN and to validate their combined prognostic role
may be of added value in stratifying patients with pros-
tate cancer, specifically those with Gleason score 6&7.
Competing interests
M. A is employer of GenomeDx Bioscience Inc. The other authors declare
that they have no competing interests.Authors’ contributions
SA carried out immunostaining, pathological analysis and wrote initial
manuscript. MA performed the bioinformatics analysis. SH carried out
pathological analysis. MD performed statistical and survival analysis. BD
designed the study. TB designed the study, carried out pathological analysis
and wrote the initial manuscript. All authors read and approved the final
manuscript.
Acknowledgement
This work was supported by the Young Investigator Award of the Prostate
Cancer Foundation, USA, Prostate Cancer Canada, and is proudly funded by
the Movember foundation, Grant #132013-01.
Author details
1Department of Pathology and Laboratory Medicine, University of Calgary
and Calgary Laboratory Services, Calgary, AB, Canada. 2Departments of
Oncology, Biochemistry and Molecular Biology, Calgary, AB, Canada.
3Southern Alberta Cancer Institute and Tom Baker Cancer Center, Calgary,
AB, Canada. 4The Prostate Cancer Center, Calgary, AB, Canada. 5Department
of Urology, University of Calgary, Calgary, AB, Canada. 6Department of
Pathology and Laboratory Medicine, Jordan University of Science and
Technology, Irbid, Jordan.
Received: 16 January 2014 Accepted: 3 March 2014
Published: 7 March 2014
References
1. Hsing AW, Tsao L, Devesa SS: International trends and patterns of
prostate cancer incidence and mortality. Int J Cancer 2000, 85(1):60–67.
2. Carswell BM, Woda BA, Wang X, Li C, Dresser K, Jiang Z: Detection of
prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle
biopsy specimens previously reported as negative for malignancy.
Histopathology 2006, 48(6):668–673.
3. Lu G, Villalba M, Coscia MR, Hoffman DR, King TP: Sequence analysis and
antigenic cross-reactivity of a venom allergen, antigen 5, from hornets,
wasps, and yellow jackets. J Immunol 1993, 150(7):2823–2830.
4. Fritig B, Heitz T, Legrand M: Antimicrobial proteins in induced plant
defense. Curr Opin Immunol 1998, 10(1):16–22.
5. Schuren FH, Asgeirsdottir SA, Kothe EM, Scheer JM, Wessels JG: The Sc7/
Sc14 gene family of Schizophyllum commune codes for extracellular
proteins specifically expressed during fruit-body formation. J Gen
Microbiol 1993, 139(9):2083–2090.
6. Miosga T, Schaaff-Gerstenschlager I, Chalwatzis N, Baur A, Boles E, Fournier
C, Schmitt S, Velten C, Wilhelm N, Zimmermann FK: Sequence analysis of a
33.1 kb fragment from the left arm of Saccharomyces cerevisiae chromo-
some X, including putative proteins with leucine zippers, a fungal Zn(II)
2-Cys6 binuclear cluster domain and a putative alpha 2-SCB-alpha 2
binding site. Yeast 1995, 11(7):681–689.
7. Asmann YW, Kosari F, Wang K, Cheville JC, Vasmatzis G: Identification of
differentially expressed genes in normal and malignant prostate by
electronic profiling of expressed sequence tags. Cancer Res 2002,
62(11):3308–3314.
8. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N,
Tomlins SA, Chinnaiyan AM, Shah RB: Fluorescence in situ hybridization
study shows association of PTEN deletion with ERG rearrangement
during prostate cancer progression. Mod Pathol 2009, 22(8):1083–1093.
9. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger
A, Klaren R, Grone EF, Wiesel M, Gudemann C, Küster J, Schott W, Staehler
G, Kretzler M, Hollstein M, Gröne HJ: Decrease and gain of gene
expression are equally discriminatory markers for prostate carcinoma:
a gene expression analysis on total and microdissected prostate tissue.
Am J Pathol 2002, 160(6):2169–2180.
10. Dahlman A, Rexhepaj E, Brennan DJ, Gallagher WM, Gaber A, Lindgren A,
Jirstrom K, Bjartell A: Evaluation of the prognostic significance of MSMB
and CRISP3 in prostate cancer using automated image analysis.
Mod Pathol 2011, 24(5):708–719.
11. Hoogland AM, Dahlman A, Vissers KJ, Wolters T, Schroder FH, Roobol MJ,
Bjartell AS, van Leenders GJ: Cysteine-rich secretory protein 3 and beta-
microseminoprotein on prostate cancer needle biopsies do not have
predictive value for subsequent prostatectomy outcome. BJU Int 2011,
108(8):1356–1362.
Al Bashir et al. Journal of Hematology & Oncology 2014, 7:21 Page 11 of 11
http://www.jhoonline.org/content/7/1/2112. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby
L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT: Association of
cysteine-rich secretory protein 3 and beta-microseminoprotein with out-
come after radical prostatectomy. Clin Cancer Res 2007, 13(14):4130–4138.
13. Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, Jeronimo
C, Henrique R, Lind GE, Skotheim RI, Lothe RA, Teixeira MR: Cysteine-rich
secretory protein-3 (CRISP3) is strongly Up-regulated in prostate carcin-
omas with the TMPRSS2-ERG fusion gene. PLoS One 2011, 6(7):e22317.
14. Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J,
Sauter G, Minner S, Schlomm T, Tsourlakis MC: Cysteine-rich secretory
protein 3 overexpression is linked to a subset of PTEN-deleted ERG
fusion-positive prostate cancers with early biochemical recurrence.
Mod Pathol 2012, 26(5733):42.
15. Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J,
Alaoui-Jamali MA, Bismar TA: Fascin regulates prostate cancer cell invasion
and is associated with metastasis and biochemical failure in prostate
cancer. Clin Cancer Res 2009, 15(4):1376–1383.
16. Brimo F, Vollmer RT, Friszt M, Corcos J, Bismar TA: Syndecan-1 expression
in prostate cancer and its value as biomarker for disease progression.
BJU Int 2010, 106(3):418–423.
17. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK,
Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I,
Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI,
Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL: Integrative
genomic profiling of human prostate cancer. Cancer cell 2010,
18(1):11–22.
18. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: The 2005 International
Society of Urological Pathology (ISUP) consensus conference on gleason
grading of prostatic carcinoma. Am J Surg Pathol 2005, 29(9):1228–1242.
19. Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA: Interactions and
relationships of PTEN, ERG, SPINK1 and AR in castration-resistant pros-
tate cancer. Histopathology 2012, 60(4):645–652.
20. Bismar TA, Yoshimoto M, Vollmer RT, Duan Q, Firszt M, Corcos J, Squire JA:
PTEN genomic deletion is an early event associated with ERG gene
rearrangements in prostate cancer. BJU Int 2011, 107(3):477–485.
21. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, Lotia S, Pico AR, Bader
GD, Ideker T: A travel guide to Cytoscape plugins. Nat Methods 2012,
9(11):1069–1076.
22. da Huang W, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens
R, Baseler MW, Lane HC, Lempicki RA: The DAVID Gene Functional
Classification Tool: a novel biological module-centric algorithm to func-
tionally analyze large gene lists. Genome Biol 2007, 8(9):R183.
23. Udby L, Calafat J, Sorensen OE, Borregaard N, Kjeldsen L: Identification of
human cysteine-rich secretory protein 3 (CRISP-3) as a matrix protein in
a subset of peroxidase-negative granules of neutrophils and in the
granules of eosinophils. J Leukoc Biol 2002, 72(3):462–469.
24. Udby L, Cowland JB, Johnsen AH, Sorensen OE, Borregaard N, Kjeldsen L:
An ELISA for SGP28/CRISP-3, a cysteine-rich secretory protein in human
neutrophils, plasma, and exocrine secretions. J Immunol Methods 2002,
263(1–2):43–55.
25. Kratzschmar J, Haendler B, Eberspaecher U, Roosterman D, Donner P,
Schleuning WD: The human cysteine-rich secretory protein (CRISP) family.
Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3.
Eur J Biochem 1996, 236(3):827–836.
26. Bjartell A, Johansson R, Bjork T, Gadaleanu V, Lundwall A, Lilja H, Kjeldsen L,
Udby L: Immunohistochemical detection of cysteine-rich secretory pro-
tein 3 in tissue and in serum from men with cancer or benign enlarge-
ment of the prostate gland. Prostate 2006, 66(6):591–603.
27. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA,
Squire JA: FISH analysis of 107 prostate cancers shows that PTEN
genomic deletion is associated with poor clinical outcome. Br J Cancer
2007, 97(5):678–685.
28. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O,
Zielenska M, Soares FA, Squire JA: Absence of TMPRSS2:ERG fusions and
PTEN losses in prostate cancer is associated with a favorable outcome.
Mod Pathol 2008, 21(12):1451–1460.
29. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr
P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Møller H, Reuter
VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS: Molecular
characterisation of ERG, ETV1 and PTEN gene loci identifies patients atlow and high risk of death from prostate cancer. Br J Cancer 2010,
102(4):678–684.
30. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, Levink R,
Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C,
Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper
CS, Molina A, Cox ME, Terstappen LW, de Bono JS: Characterization of ERG,
AR and PTEN gene status in circulating tumor cells from patients with
castration-resistant prostate cancer. Cancer Res 2009, 69(7):2912–2918.
31. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW,
Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL:
TMPRSS2-ERG gene fusion is not associated with outcome in patients
treated by prostatectomy. Cancer Res 2009, 69(4):1400–1406.
doi:10.1186/1756-8722-7-21
Cite this article as: Al Bashir et al.: Cysteine- rich secretory protein 3
(CRISP3), ERG and PTEN define a molecular subtype of prostate cancer
with implication to patients’ prognosis. Journal of Hematology & Oncology
2014 7:21.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
